CBG is known to be a sort of “primal cannabinoid” and is the mother and building block for what later can become CBD, THC or many other cannabinoids or terpenes.
In many ways, cannabinoid science and medicine is still in its infancy. Consider for a moment that it has only been in recent years that we’ve realized that there was something other than cannabis’ main active ingredient, THC, that is worth paying close attention to – like our old friend cannabidiol (aka CBD), for instance.
Of the over 100-plus cannabinoids potentially found in the plant itself, only a small fraction has been studied with any amount of thoroughness, and of those even less are available in useful amounts to the general public. However, that has already begun to change. With the rapid rate of exchange of information and genetics, we have begun to see a blossoming of diversity in unique cannabinoid preparations available on the market.
Cannabigerol (CBG) is a valuable cannabinoid that occurs with large enough frequency in the plant to warrant greater exploration. CBG is known to be a sort of “primal cannabinoid” and is the mother and building block for what later can become CBD, THC or many other cannabinoids or terpenes (depending on the genetic profile within a particular plant).
Research has shown that CBG exhibits anti-microbial and potentially anti-carcinogenic properties. As a painkiller, studies have shown that it has even greater therapeutic potential than THC. There are many other possible uses for CBG as well – by interfering with the uptake of our essential neurotransmitters such as GABA, serotonin and norepinephrine it may offer significant sedative, anti-depressant and anti-spasmodic properties.
CBG seems as if it could be a cannabinoid with dizzying potential.
It makes sense that some researchers call CBG a “stem cell” – not only does it most often transform into other related compounds as the plant grows to maturity, but CBG also seems to have a similar diverse healing potential as that of human stem cell therapy.
